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Abstract
Introduction Peripartum cardiomyopathy (PPCM) is an important cause of pregnancy-associated heart failure worldwide. 
Although a significant number of women recover their left ventricular (LV) function within 12 months, some remain with 
persistently reduced systolic function.
Methods Knowledge gaps exist on predictors of myocardial recovery in PPCM. N-terminal pro-brain natriuretic peptide 
(NT-proBNP) is the only clinically established biomarker with diagnostic value in PPCM. We aimed to establish whether 
NT-proBNP could serve as a predictor of LV recovery in PPCM, as measured by LV end-diastolic volume (LVEDD) and 
LV ejection fraction (LVEF).
Results This study of 35 women with PPCM (mean age 30.0 ± 5.9 years) had a median NT-proBNP of 834.7 pg/ml 
(IQR 571.2–1840.5) at baseline. Within the first year of follow-up, 51.4% of the cohort recovered their LV dimensions 
(LVEDD < 55 mm) and systolic function (LVEF > 50%). Women without LV recovery presented with higher NT-proBNP 
at baseline. Multivariable regression analyses demonstrated that NT-proBNP of ≥ 900 pg/ml at the time of diagnosis was 
predictive of failure to recover LVEDD (OR 0.22, 95% CI 0.05–0.95, P = 0.043) or LVEF (OR 0.20 [95% CI 0.04–0.89], 
p = 0.035) at follow-up.
Conclusions We have demonstrated that NT-proBNP has a prognostic value in predicting LV recovery of patients with 
PPCM. Patients with NT-proBNP of ≥ 900 pg/ml were less likely to show any improvement in LVEF or LVEDD. Our find-
ings have implications for clinical practice as patients with higher NT-proBNP might require more aggressive therapy and 
more intensive follow-up. Point-of-care NT-proBNP for diagnosis and risk stratification warrants further investigation.
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Introduction
Peripartum cardiomyopathy (PPCM) is an important cause 
of pregnancy-associated heart failure and occurs in women 
towards the end of pregnancy or within the first five months 
after delivery [1, 2]. Although up to 46% of patients with 
PPCM recover their left ventricular (LV) function within 
6 months, 23% remain with severely impaired LV systolic 
function and develop chronic heart failure [3].
Despite recent advances in the management of PPCM, 
predictors of myocardial recovery remain poorly understood. 
Previous baseline clinical factors that have been shown to 
influence LV recovery include LVEF, [4–6] LV dimensions, 
[5, 7, 8] presence of LV thrombus, [7] right ventricular (RV) 
systolic dysfunction [9] and African-American ethnicity [5, 
7, 10, 11]. Identification of predictors of LV recovery could 
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help to risk stratify patients at the time of PPCM diagnosis, 
and identify those patients that may benefit from more inten-
sive therapy and follow-up.
B-type natriuretic peptide (BNP) and its prohormone, 
N-terminal B-type natriuretic peptide (NT-proBNP), are 
released in response to cardiac wall stress, [12, 13] and are 
important biomarkers in the diagnosis of heart failure [14]. 
However, the role of natriuretic peptides is predominantly 
to rule out heart failure. Previous studies have shown that 
NT-proBNP is elevated at the time of diagnosis of PPCM 
[15, 16] and a diagnosis of PPCM is unlikely if a patient 
presents with BNP < 100 pg/ml or NT-proBNP < 300 pg/
ml [2]. Furthermore, NT-proBNP is useful in differentiat-
ing healthy postpartum women from those with PPCM or 
pre-eclampsia [6, 15, 17].
While elevated NT-proBNP levels have been shown 
to predict mortality and cardiovascular events in patients 
with heart failure, even amongst those who were asymp-
tomatic, [18] little is known about the prognostic value of 
NT-proBNP amongst patients with PPCM. In this study, we 
aimed to assess whether NT-proBNP could serve as predic-
tor of LV recovery in PPCM.
Methods
Study design and recruitment
Women with PPCM, seen at the dedicated Cardiomyopathy 
Clinic at Groote Schuur Hospital, were recruited between 
2013 and 2018. Patients were referred from primary or 
secondary care facilities or within the tertiary/quaternary 
hospital, and assessed by a team of cardiologists and heart 
failure specialists.
Inclusion criteria included: (1) primary diagnosis of 
PPCM, i.e. documented clinical evidence of LV systolic 
dysfunction towards the end of pregnancy or during the first 
five months postpartum; (2) no other identifiable causes of 
heart failure; (3) LVEF ≤ 45% on presentation confirmed by 
transthoracic echocardiography. Exclusion criteria were: (1) 
patient unable to give informed consent; (2) other identifi-
able causes of heart failure; and (3) patients younger than 
18 years.
This study was approved by the University of Cape 
Town’s Faculty of Health Sciences Human Research Ethics 
Committee (HREC ref no R033/2013), and complied with 
the Declaration of Helsinki. All patients provided written 
informed consent prior to study entry.
Eligible patients were enrolled at the baseline visit, at 
which time their medical and obstetric history, New York 
Heart Association (NYHA) functional class, clinical exami-
nation findings and prescribed medication were recorded. 
All patients had 12-lead electrocardiogram (ECG) and 
echocardiogram at the baseline visit. Blood was collected 
at the baseline visit for the measurement of full blood count, 
renal function and NT-proBNP.
12‑lead ECG
A resting 12-lead ECG was performed for all patients at 
baseline using a MAC 5500 HD (GE Healthcare, Chicago, 
Illinois, USA) machine. The ECG was analysed for heart 
rate, rhythm, QRS duration, LV hypertrophy (LVH) by 
Sokolow–Lyon criteria [19], and a QT interval measure-
ment, corrected by Bazett’s formula (QTcB) [20]. Sinus 
tachycardia was defined as a heart rate of ≥ 100 beats per 
minute (bpm). A QTcB interval of ≥ 460 ms was regarded 
as prolonged [21].
Echocardiographic assessment
Echocardiography was performed at the time of diagnosis 
and at follow-up. Two-dimensional and targeted M-mode 
echocardiography with Doppler colour flow mapping were 
performed using either a Philips CX50 (Philips, Amster-
dam, Netherlands) or a VIVIDi (General Electric Company, 
Fairfield, Connecticut, USA) echocardiography machine. LV 
dimensions (i.e. LV end-diastolic diameter [LVEDD] and LV 
end-systolic diameter [LVESD]) and global systolic function 
(LV ejection fraction [LVEF]) were measured according to 
the guidelines endorsed by the American Society of Echo-
cardiography [22].
Blood tests
Blood samples were taken at the baseline visit. Full blood 
count and renal function were analysed by the National 
Health Laboratory Service (NHLS) at Groote Schuur Hos-
pital. For NT-proBNP testing, plasma or serum was sepa-
rated by centrifugation and aliquots were stored at − 80 °C. 
NT-proBNP was measured for each participant using the 
BNP Fragment EIA kit (Biomedica; Vienna, Austria). NT-
proBNP values were converted to pg/ml as recommended by 
current clinical practice guidelines.
Outcome
We considered two separate echocardiographic measures 
for LV recovery, i.e. LVEDD < 55 mm and LVEF ≥ 50% 
within the 12-month follow-up period. Patients who did not 
fulfil these echocardiographic criteria at follow-up echocar-
diogram, and those who died within the study period, were 
considered to have no LV recovery.
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Statistical analysis
Data were collected on Research Electronic Data Capture 
(REDCap Version 9.5.13), a secure electronic database 
hosted by the University of Cape Town [23], before being 
exported to Stata (Version 14.2, StataCorp, College Sta-
tion, TX, USA) for statistical analysis. Descriptive statis-
tics were used to summarise data. Distribution of data was 
determined by Shapiro–Wilk test. Continuous variables 
were summarised as means with standard deviations (SD) 
for parametric data or median with interquartile range 
(IQR) for non-parametric data. Categorical variables were 
expressed as frequencies and percentages. Considering 
the median NT-proBNP at baseline, we used a cut-off 
value of 900 pg/ml as a dichotomous variable according 
to which patients were stratified. Where appropriate, we 
used a Kruskal–Wallis or Wilcoxon rank-sum test (for 
continuous variables) and chi-squared or Fisher’s exact 
test (for categorical variables), to compare outcome meas-
ures at follow-up, and whether patients had an initial NT-
proBNP of ≥ or < 900 pg/ml. Univariable and multivari-
able logistic regression analyses were done to determine 
the association between NT-proBNP value of ≥ 900 pg/ml 
at presentation and LV recovery (i.e. LV dimension and 
systolic function) at follow-up. NT-proBNP was adjusted 
for age and BMI. A p value of < 0.05 was considered to 
indicate statistical significance.
Results
This cohort of 35 women with PPCM had a mean age 
of 30.0 ± 5.9 years (Table 1). Almost half of the cohort 
(45.7%) was multiparous (parity > 3). At the time of 
diagnosis, 40% had a NYHA functional class III or IV. 
Overall, the patients presented with a mean heart rate of 
90.6 ± 19.6 bpm and a median systolic and diastolic blood 
pressure of 112 mmHg (IQR 105—138) and 76 mmHg 
(IQR 70—85), respectively. On echocardiography, the 
median LVEF was 31% (IQR 24—39), with an LVEDD 
of 58 mm (IQR 53—64) and LA diameter of 35 mm (IQR 
33—39). The median NT-proBNP at the time of diagno-
sis was 834.7 pg/ml (IQR 571.2—1840.5). The median 
Hb was 11.9 g/dL (IQR 9.9—12.9), and there was no 
renal impairment. By the time of discharge, heart failure 
therapy consisted of beta-blocker (94.3%), angiotensin 
converting enzyme (ACE)-inhibitor or angiotensin recep-
tor blocker (ARB) (80%), mineralocorticoid-receptor 
antagonist (MRA) (45.7%) and loop diuretics (91.4%). 
The dopamine agonist, bromocriptine, was prescribed to 
41.1% of the patients in this cohort.
Recovery of LV dimensions
Figure  1 shows that most women with PPCM showed 
overall improvement in LV dimensions at follow-up. How-
ever, 18 women (51.4%) recovered their LV dimensions 
(LVEDD < 55 mm) within the first year after diagnosis. As 
depicted in Table 1, women who showed recovery of LV 
dimensions, had a significantly lower heart rate (83 ± 15 vs 
98 ± 22 bpm, p = 0.025) and were less likely to have sinus 
tachycardia (11 vs 59%, p = 0.012) at initial presentation. The 
baseline QTc interval was longer, however, in patients who 
failed to recover their LV dimensions (470 [IQR 453—480] 
vs. 443 ms [IQR 414—456], p = 0.030). The baseline LVEF 
did not predict recovery of LV dimensions. The initial NT-
proBNP was lower in those with recovery of LV dimensions 
within 12 months (622.3 [IQR 534—1000.7] vs. 1020.1 pg/
ml [IQR 713.4—1865.4], p = 0.041). As depicted in Fig. 1a 
and b, the LVEDD decreased at follow visits, regardless of 
whether the initial NT-proBNP level measured ≥ or < 900 pg/
ml (OR 0.42 [95% 0.06—2.95], p = 0.380), though the gradi-
ent of decline was greater in those with NT-proBNP level 
measured < 900 pg/ml at baseline. Women with an NT-
proBNP of ≥ 900 pg/ml had significantly higher LVEDD 
at follow-up (58 ± 6.66 vs 49.9 ± 5.05 mm, p < 0.001). As 
shown in Table 2, multivariable regression analysis found 
that an NT-proBNP of ≥ 900 pg/ml at the time of PPCM 
diagnosis was predictive of failure to achieve an LVEDD 
within normal range (LVEDD < 55 mm) at follow-up (OR 
0.22 [95% CI 0.05–0.95] p = 0.043).
Recovery of LV systolic function
Within the first year of follow-up, 51.4% of the cohort 
recovered their systolic function (LVEF > 50%). Women 
who did not recover systolic function by 12 months were 
more likely to present with a NYHA functional class III or 
IV (58.8 vs. 22.2%; p = 0.041) and sinus tachycardia (52.9 
vs. 11.1%; p = 0.012) at the time of first diagnosis. There 
was no significant difference in haemoglobin, creatinine or 
hs-CRP at baseline between women with LV recovery and 
LV non-recovery.
Although not statistically significant, there was a nota-
ble difference in the initial NT-proBNP values between 
those who recovered their LV function by 12 months and 
those who did not (693.2  pg/ml [IQR 543.9—1000.7] 
vs. 1066.2 pg/ml [682.5—1962], p = 0.065). More than 
two-thirds of those who did not recover their LV func-
tion within one year presented initially with NT-proBNP 
levels of ≥ 900 pg/m (68.4 vs. 31.3%, p = 0.028). Patients 
with a baseline NT-proBNP < 900  pg/ml showed more 
consistent recovery of their systolic function at follow-up 
(Fig. 1c) (LVEF of 53%, IQR 49–56), whereas there was 
more variation in LVEF at follow-up amongst those patients 
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with NT-proBNP ≥ 900 pg/ml (LVEF of 42%, IQR 31–51, 
p = 0.045) (Fig. 1d). Indeed, women with NT-proBNP lev-
els of ≥ 900 pg/ml had a lower likelihood of LV functional 
improvement (OR 0.12 [95% CI 0.02—0.69], p = 0.017). 
As depicted in Table 2, multivariable regression analysis 
found NT-proBNP level of ≥ 900 pg/ml to be predictive of 
Table 1  Baseline characteristics (including demographic, clinical, therapeutic, electrocardiographic and echocardiographic characteristics) pre-
dicting recovery of LV dimensions and systolic function with one year
ACE-i Angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, BMI Body mass index, DBP diastolic blood pressure, hs-
CRP high-sensitivity C-reactive protein, IFN-γ interferon gamma, LVEDD left ventricular end-diastolic diameter, LVEF left ventricular ejection 
fraction, LVH left ventricular hypertrophy, MRA mineralocorticoid-receptor antagonists, NT-proBNP N-terminal pro-B-type natriuretic peptide, 
NYHA FC New York Heart Association Functional Class, QTcB corrected QT interval by Bazett’s formula, SBP systolic blood pressure














N = 35 N = 18 N = 17 N = 18 N = 17
Age (years) Mean ± SD 30.0 ± 5.9 29.7 ± 6.9 30.3 ± 4.8 0.278 30.1 ± 6.8 29.8 ± 5.0 0.692
BMI (kg/m2) Mean ± SD 25.3 ± 4.9 24.38 ± 4.5 26.31 ± 5.27 0.192 24.6 ± 4.8 26.1 ± 5.1 0.222
Breastfeeding (months) Median 
(IQR)
16 (5–30) 16 (4–30) 24.5 (5–17) 0.972 16 (6–30) 24 (3–36) 0.778
Parity 1 N (%) 7 (20) 3 (16.67) 4 (23.5) 0.463 2 (11.1) 5 (29.4) 0.420
Parity 2 N (%) 12 (34.3) 8 (44.4) 4 (23.5) 7 (38.9) 5 (29.4)
Parity ≥ 3 N (%) 16 (45.7) 7 (38.9) 9 (52.9) 9 (50) 7 (41.2)
NYHA FC III or IV N (%) 14 (40) 6 (33.3) 8 (47) 0.407 4 (22.2) 10 (58.8) 0.041




110 (101—138) 120 (108–133) 0.079 115 (101–138) 110 (108–120) 0.656
DBP (mmHg) Median 
(IQR)
76 (70–85) 70 (70–85) 80 (70–80) 0.214 75 (70–85) 76 (70––80) 0.947
Heart rate (per min) Mean ± SD 90.6 ± 19.6 83 ± 15 98 ± 22 0.025 85 ± 15 97 ± 22 0.072
Sinus tachycardia N (%) 11 (31.4) 2 (11) 9 (52.9) 0.012 2 (11.1) 9 (52.9) 0.012
QRS width (ms) Median 
(IQR)
85 (80–92) 84 (79–89) 86 (82—94) 0.383 84 (80–94) 86 (80–92) 0.967
LVH (Sokolow-Lyon) N (%) 9 (25.7) 5 (28) 4 (23) 1.000 4 (22.2) 5 (29.4) 0.711




443 (414–456) 470 (453–480) 0.030 448 (416–474) 463 (436–470) 0.572




35 (33—39) 35 (33—37) 36 (34—44) 0.235 35 (33—37) 35 (34—41) 0.408
LVEDD (mm) Median 
(IQR)
58 (53—64) 57 (51—62) 60 (55—65) 0.137 59.5 (51—64) 57 (55—65) 0.364
LVEF (%) Median 
(IQR)
31 (24—39) 33 (27—40) 28 (24—38) 0.330 31 (24—38) 32 (25—39) 0.655




11.2 (9.4—12.5) 12.1 (11.5—13.1) 0.137 11.9 (9.9—12.7) 11.9 (10.8—
13.1)
0.609
Creatinine (µmol/L) Median 
(IQR)
61 (54—72) 61 (54 -67) 64 (53 -77) 0.310 63 (55—70) 61 (49—76) 0.509













1.7 (1.2—21.1) 4.8 (1—8.2) 0.872 3.3 (1.5—13.6) 1.46 (0.9—16.6) 0.430














N (%) 16 (45.7) 5 (27.8) 11 (64.7) 0.028 5 (31.3) 13 (68.4) 0.028
Loop diuretic N (%) 32 (91.4) 15 (83.3) 17 (100) 0.229 15 (83.3) 17 (100) 0.229
MRA N (%) 16 (45.7) 7 (38.9) 9 (53) 0.404 10 (55.6) 6 (35.3) 0.315
ACE-i / ARB N (%) 28 (80) 15 (83) 14 (82) 1.000 14 (77.8) 15 (88.2) 0.658
Beta-blocker N (%) 33 (94.3) 17 (94) 16 (94) 1.000 17 (94.4) 16 (94.1) 1.000
Bromocriptine N (%) 14/34 (41.1) 10/17 (58.8) 4 (23.5) 0.080 9/17 (52.9) 5 (29.4) 0.163
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persistent impaired systolic function (LVEF < 50%) at fol-
low-up (OR 0.20 [95% CI 0.04—0.89], p = 0.035).
Factors associated with increased NT‑proBNP
When adjusted for age and BMI, an NT-proBNP level 
of ≥ 900 pg/ml remained a significant predictor of recovery 












































NT proBNP > 900 pg/ml
A
C D
BNT-pro  < 9 0 pg/ml
NT-proBNP < 9  g/ml
NT-pr P  900 pg/ml
NT-pr P  900 pg/ml
Fig. 1  Change of LV dimensions and LV systolic function between diagnosis and one-year follow-up as classified by NT-proBNP < or ≥ 900 pg/
ml
Table 2  Univariable and 
multivariable logistic regression 
analysis of predictors of 
recovery of LV dimensions and 
systolic function within one 
year
BMI body mass index, LVEDD left ventricular end-diastolic diameter, LVEF left ventricular ejection frac-
tion, NT-proBNP N-terminal pro-B-type natriuretic peptide
Univariable regression analysis Multivariable regression analysis
OR 95% CI P value OR 95% CI P value
Recovery of LV dimensions (LVEDD < 55 mm)
 Age (years) 0.98 0.88—1.10 0.770 1.02 0.89—1.16 0.769
 BMI 0.92 0.80—1.06 0.247 0.93 0.79—1.09 0.359
NT-proBNP ≥ 900 pg/ml 0.21 0.05—0.88 0.033 0.22 0.05—0.95 0.043
Recovery of LV systolic function (LVEF ≥ 50%)
Age (years) 1.01 0.91—1.13 0.865 1.05 0.92—1.19 0.458
 BMI 0.93 0.81—1.08 0.345 0.94 0.80—1.10 0.439
 NT-proBNP ≥ 900 pg/ml 0.21 0.05—0.88 0.033 0.20 0.04—0.89 0.035





P = 0.750  P = 0.467  
P = 0.043  
P = 0.348  
P = 0.012  P = 0.085  























































































































































P = 0.217  
P = 0.381  
Fig. 2  Correlation between NT-proBNP and clinical, biochemical and echocardiographic parameters
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and systolic function (OR 0.20 [95% CI 0.04—0.89], 
p = 0.035) within 12 months (Table 2).
There was no correlation between NT-proBNP 
and blood pressure (SBP r =  – 0.06, p = 0.751; DBP 
r = -0.127, p = 0.467) – Fig. 2. Similarly, NT-proBNP 
did not correlate with BMI or creatinine. However, there 
was a modest correlation between NT-proBNP levels and 
heart rate (r = 0.344, p = 0.043) and LVEDD (r = 0.420; 
p = 0.012).
Table 3 depicts the clinical factors that were associ-
ated with higher baseline NT-proBNP levels. Women with 
NT-proBNP ≥ 900 pg/ml at the time of diagnosis, had a 
higher heart rate (98 vs 85 bpm; p = 0.028), a tendency 
towards a larger left atrial (LA) diameter (37 vs 35 mm, 
p = 0.091), and significantly increased LVEDD (62.5 vs 
55 mm; p = 0.027). Furthermore, these patients presented 
with a significantly lower LVEF (26 vs 35%; p = 0.035) at 
the time of diagnosis. There was no difference in param-
eters that are known to influence NT-proBNP (i.e. BMI, 
creatinine).
Discussion
In this study, we show that women with PPCM present with 
markedly increased NT-pro-BNP levels at the time of diag-
nosis. In this regard, a baseline NT-proBNP ≥ 900 pg/ml 
is predictive of failure to recover LV systolic function and 
dimensions at one-year follow-up. Importantly, NT-proBNP 
levels are usually not elevated during normal pregnancy or 
healthy postpartum period [24]. NT-proBNP levels in our 
cohort were higher than what has been reported for women 
Table 3  Differences in baseline 
characteristics as classified by 
NT-proBNP < or ≥ 900 pg/ml
ACE-i Angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, BMI Body mass 
index, DBP diastolic blood pressure, hs-CRP high-sensitivity C-reactive protein, IFN-γ interferon gamma, 
LVEDD left ventricular end-diastolic diameter, LVEF left ventricular ejection fraction, LVH left ventricular 
hypertrophy, MRA mineralocorticoid-receptor antagonists, NT-proBNP N-terminal pro-B-type natriuretic 
peptide, NYHA FC New York Heart Association Functional Class, QTcB corrected QT interval by Bazett’s 
formula, SBP systolic blood pressure
NT-proBNP < 900 pg/ml NT-proBNP ≥ 900 pg/ml P value
N = 19 N = 16
Age (years) Mean ± SD 29.1 ± 6.4 31.1 ± 5.2 0.246
BMI (kg/m2) Mean ± SD 24.6 ± 5.2 26.2 ± 4.5 0.289
Breastfeeding (months) Median (IQR) 20 (6—30) 16 (3—34) 0.832
Parity 1 N (%) 3 (15.8) 4 (25) 0.821
Parity 2 N (%) 7 (36.8) 5 (31.3)
Parity ≥ 3 N (%) 9 (47.4) 7 (43.8)
NYHA FC III or IV N (%) 4 (21.1) 10 (62.5) 0.018
SBP (mmHg) Median (IQR) 118 (101—138) 111 (107—129) 0.702
DBP (mmHg) Median (IQR) 76 (70—85) 75 (66—85) 0.738
Heart rate (per minute) Mean ± SD 85 ± 16.8 98 ± 20.6 0.028
Sinus tachycardia N (%) 3 (15.8) 8 (50) 0.065
QRS width (ms) Median (IQR) 84 (80—88) 86 (82—94) 0.451
LVH (Sokolow–Lyon) N (%) 5 (26.3) 4 (25) 1.000
QTcB (ms) Median (IQR) 454 (415—470) 459 (436—470) 0.621
Left atrial diameter (mm) Median (IQR) 35 (32—37) 37 (34—43) 0.091
LVEDD (mm) at diagnosis Median (IQR) 55 (51—60) 62.5 (55—67.5) 0.027
LVEF (%) at diagnosis Median (IQR) 35 (27—40) 26 (21.5—36.5) 0.035
LVEDD (mm) at follow-up Median (IQR) 50 (46—55) 58 (51—61) 0.001
LVEF (%) at follow-up Median (IQR) 53 (49—56) 42 (31—51) 0.045
Haemoglobin (g/dL) Median (IQR) 11.7 (9.4—12.9) 12 (10.4—12.7) 0.947
Creatinine (µmol/L) Median (IQR) 61 (53—67) 64 (54—77) 0.249
IFN-γ (I.U./ml) Median (IQR) 13.3 (10.7—13.6) 13.2 (13.0—13.8) 0.531
hs-CRP (mg/l) Median (IQR) 1.7 (1.0—4.9) 4.6 (1.1—39.3) 0.403
Loop diuretic N (%) 17 (89.5) 15 (93.8) 1.000
MRA N (%) 7 (36.8) 9 (56.3) 0.251
ACE-i / ARB N (%) 14 (73.7) 15 (93.8) 0.187
Beta-blocker N (%) 18 (94.7) 15 (93.8) 1.000
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during normal pregnancy and healthy postpartum period, 
[15, 24] and those reported for women with pre-eclamp-
sia [17]. This corresponds to what has previously been 
reported for patients with PPCM in South Africa, Germany 
and China [6, 15, 16]. The NT-proBNP values seen in this 
cohort (mean 834.7 pg/ml), however, were lower than those 
recently reported for the 739 patients included in the Euro-
pean Observational Research Project (EORP) on PPCM, 
where the median NT-proBNP was 3308 pg/ml [3].
Contemporary heart failure guidelines recommend 
natriuretic peptides as the biomarker of choice in diagnostic 
work-up of patients with heart failure [25]. In this regard, 
the diagnostic role of BNP or NT-proBNP is predominantly 
to exclude heart failure in peripartum patients. In a study by 
Malhame et al., a BNP cut-off value of < 111 pg/ml excluded 
heart failure in pregnant and postpartum women [26]. For 
PPCM, a threshold of < 100 pg/ml for BNP and < 300 pg/ml 
for NT-proBNP was proposed to rule out heart failure during 
pregnancy or the postpartum period [27].
Natriuretic peptides have also been studied for its prog-
nostic value during pregnancy and the postpartum period. 
Normal BNP levels (< 100 pg/ml) have been shown to have 
a negative predictive value for adverse maternal events in 
pregnant women with heart disease [24]. In women with 
congenital heart disease, BNP levels > 128 pg/ml measured 
at 20-week gestation predicted adverse cardiovascular events 
later in pregnancy [28].
The predictive value of NT-proBNP in patients with 
mild to moderate heart failure was studied in a sub-study of 
the COPERNICUS trial (n = 1,011) in which patients were 
stratified according to whether their NT-proBNP levels were 
above or below the median value of the cohort [29]. Hart-
mann et al. described increased mortality and rehospitalisa-
tion for heart failure amongst patients with an NT-proBNP 
above the median of the cohort [29]. Considering the median 
baseline NT-proBNP in this cohort, we chose an arbitrary 
cut-off value of 900 pg/ml according to which our patients 
were classified. We found that patients with NT-pro-BNP 
of ≥ 900 pg/ml had significantly higher LVEDD and signifi-
cantly lower LVEF at one-year follow-up. Although most 
patients showed some improvement in LVEDD and LVEF 
at follow-up, women with NT-pro-BNP of ≥ 900 pg/ml were 
less likely to recover their LV dimensions and systolic func-
tion within normal range within one-year follow-up.
When interpreting NT-proBNP levels in heart failure, 
various clinical factors need to be considered. The level of 
natriuretic peptides increases with age, and therefore, higher 
cut-off values are suggested for the elderly. Whereas obesity 
lowers the concentration of natriuretic peptides, renal dis-
ease and atrial arrhythmias (atrial fibrillation (AF) in par-
ticular) are associated with higher NT-proBNP levels. None 
of the patients in this cohort had AF; this was not surprising, 
as AF has previously been described to be rare in PPCM 
[30]. Furthermore, the median creatinine was 61 µmol/L in 
this cohort and there was no significant correlation between 
creatinine and NT-proBNP. Adjusting for age and BMI, 
baseline NT-proBNP ≥ 900 pg/ml was a predictor of failure 
to recover LV dimensions and systolic function within one 
year in this South African cohort. In a Chinese cohort of 71 
patients with PPCM, Li et al. reported that NT-proBNP lev-
els of > 1860 pg/ml were associated with a threefold increase 
in persistent LV systolic dysfunction at follow-up [16]. In 
contrast, Biteker et al. did not find BNP to be predictive of 
recovery of LV dimensions and systolic function in a cohort 
of 43 women with PPCM from Turkey [31].
Although our study showed that in most patients, there 
was an improvement in LV dimensions and systolic function, 
some remained with an LVEDD > 55 mm and LVEF < 50% 
at follow-up. We found that women with baseline NT-
proBNP ≥ 900 pg/ml were more likely to show no improve-
ment in their LV systolic function at one-year follow-up. 
This is supported by previous work by Forster et al. who 
reported that NT-proBNP levels were significantly higher 
in those women who did not show an improvement of at 
least 10 percentage units (e.g. 25–35%). In their study, NT-
proBNP levels remained significantly higher in those who 
did not improve their LV function [15].
Inflammation, increased levels of oxidative stress and 
systemic angiogenic imbalance appear to play a crucial role 
in the pathophysiology of PPCM. Through unknown mecha-
nisms, increased levels of oxidative stress cause a cleavage 
of prolactin into a 16-kDa fragment, which causes endothe-
lial dysfunction and induces cardiomyocyte apoptosis [32, 
33]. Moreover, auto-immune mechanisms have been sug-
gested to be involved in the pathogenesis of PPCM [34, 35]. 
More severe forms of the disease have been shown to have 
higher levels of auto-antibodies. In this regard, circulating 
auto-antibodies against cardiac sarcomeric myosin (MHC) 
and troponin I (TnI) were also associated with higher levels 
of NT-proBNP. Indeed, patients with auto-antibodies have 
been described to have lower rates of LV recovery [35].
Increased NT-proBNP levels are associated with LV 
remodeling [36]. In this cohort, elevated levels of NT-
proBNP tended to be associated with a lower LVEF. How-
ever, there was there was a significant correlation between 
LVEDD and NT-proBNP in this cohort. As expected, those 
with NYHA functional class III or IV also had higher lev-
els of NT-proBNP, in keeping with a more severe stage of 
heart failure. Although there was no correlation between sys-
tolic or diastolic blood pressure and NT-proBNP, we found 
a positive correlation between heart rate and NT-proBNP 
levels. Those patients with sinus tachycardia at time of ini-
tial diagnosis, had significantly higher levels of NT-proBNP. 
This underlines the importance of recognising the presence 
of sinus tachycardia in patients with heart failure, as sinus 
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tachycardia has previously been reported as a predictor of 
poor outcome in PPCM [37].
Although not explored in this study, point-of-care 
(POC) NT-proBNP tests have previously been used in 
patients with heart failure. The benefit of POC testing is its 
ease of use, affordability and the immediate availability of 
the result [38]. Therefore, NT-proBNP bedside testing in 
patients with PPCM is an exciting prospect, especially in 
health care centres in low- and middle-income countries, 
where echocardiography is not readily available [14]. POC 
NT-proBNP testing may potentially assist the primary care 
physicians with diagnosis of PPCM, risk stratification, and 
timely referral [39]. The role of POC NT-proBNP testing, 
however, still needs to be studied in PPCM.
Limitations
As this is a single-centre study conducted at a tertiary hos-
pital, where the most severe cases of PPCM are generally 
seen, there is a possibility of referral bias. Furthermore, 
considering that PPCM is a rare disease, we acknowledge 
that the small sample size of this study might have affected 
the precision of estimates, especially in the logistic regres-
sion analyses. We therefore encourage validation of our 
findings in a larger, multi-centred cohort.
This study also lacks a control group and NT-proBNP 
measurements at follow-up. The slope of change in NT-
proBNP levels in patients with PPCM might provide 
important information regarding the changes of LV 
recovery and selection of correct heart failure treatment 
in future studies.
We acknowledge that RV function, which has previously 
been shown to have important prognostic value in PPCM, [9] 
was not assessed in this study. Future studies should evaluate 
the impact of RV size and function on NT-pro-BNP levels 
in PPCM.
Conclusions
We demonstrate the prognostic value of NT-pro-BNP for LV 
recovery in PPCM. We have shown that NT-proBNP may be 
useful in the risk stratification of patients with PPCM and 
may be used to implement more intensive treatment strate-
gies of patients who have an NT-proBNP ≥ 900 pg/ml at 
diagnosis and individualise follow-up regimens. The appli-
cation of POC NT-proBNP testing should be further studied 
for its use of diagnosis and risk stratification for patients 
with PPCM.
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